AstraZeneca: encouraging results for type 2 diabetes drug
(CercleFinance.com) - AstraZeneca reports that results from a Phase III trial in children with type 2 diabetes offer "hope".
Results showed a significant reduction in A1C (a marker of average blood glucose) in patients with type 2 diabetes (T2D) treated with Forxiga (dapagliflozin) compared with patients receiving placebo.
The significant reduction in HbA1c that was observed in patients receiving Forxiga may indicate a reduction in disease progression and complications, a related medical source said.
The results were presented today at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) and published simultaneously in the New England Journal of Medicine Evidence.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Results showed a significant reduction in A1C (a marker of average blood glucose) in patients with type 2 diabetes (T2D) treated with Forxiga (dapagliflozin) compared with patients receiving placebo.
The significant reduction in HbA1c that was observed in patients receiving Forxiga may indicate a reduction in disease progression and complications, a related medical source said.
The results were presented today at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) and published simultaneously in the New England Journal of Medicine Evidence.
Copyright (c) 2023 CercleFinance.com. All rights reserved.